Interferon therapy for hepatocellular carcinoma patients with low HCV-RNA levels

Shingo Miyaguchi, Tetsu Watanabe, Hiyori Takahashi, Mitsuyasu Nakamura, Hidetsugu Saito, Hiromasa Ishii

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Background/Aims: Interferon-alfa is widely used for the treatment of chronic hepatitis C, and has been thought to have a preventive effect on the development of hepatocellular carcinoma. Hepatocellular carcinoma develops from chronic liver diseases such as chronic hepatitis C or liver cirrhosis. We studied the effect of interferon for liver cirrhosis with hepatocellular carcinoma after treating hepatocellular carcinoma itself. Methodology: To evaluate the preventive effect of this drug on local recurrence and/or new development of primary tumor after clearance of hepatitis C virus, 46 patients with hepatocellular carcinoma with low HCV-RNA level were randomized to receive recombinant interferon-alfa 2b (n=22) or not (n=24) after being treated by transcatheter arterial chemoembolization and percutaneous ethanol injection therapy. In the interferon-treated group, patients received 3 million international units of interferon-alfa 2b intramuscularly three times a week for 4 months. In both groups, transcatheter arterial chemoembolization followed by percutaneous ethanol injection therapy was performed as an initial treatment and these therapies were repeated every 4-6 months. Serum HCV-RNA levels of all 46 patients were under 0.5Meq/mL by branched DNA probe assay. Results: In the interferon-treated group, 11 of the 22 (50%) patients were HCV-RNA negative at the 6 months after completing the course of interferon therapy. HCV-RNA was undetectable during the observation period in 2 of the 24 (9.5%) patients in the untreated group. The survival rate in the interferon-treated group was significantly higher than that in the untreated group (P=0.01 by the log-rank test). Though there was no significant difference in the incidence of local recurrence in both groups, the incidence of secondary hepatocellular carcinoma was significantly lower in the interferon-treated group than that in the untreated group. Cox proportional hazards regression analysis validated interferon treatment as an independent predictor of hepatocellular carcinoma prognosis. Conclusions: We concluded that, if HCV-RNA level is low, interferon may be a therapy of choice in combination with transcatheter arterial chemoembolization and percutaneous ethanol injection therapy for the treatment of hepatocellular carcinoma.

Original languageEnglish
Pages (from-to)724-729
Number of pages6
JournalHepato-Gastroenterology
Volume49
Issue number45
Publication statusPublished - 2002
Externally publishedYes

Fingerprint

Interferons
Hepatocellular Carcinoma
RNA
interferon alfa-2b
Therapeutics
Ethanol
Chronic Hepatitis C
Liver Cirrhosis
Injections
Branched DNA Signal Amplification Assay
Recurrence
Incidence
DNA Probes
Interferon-alpha
Hepacivirus
Liver Diseases
Chronic Disease
Survival Rate
Regression Analysis
Observation

Keywords

  • HCC
  • Interferon

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Miyaguchi, S., Watanabe, T., Takahashi, H., Nakamura, M., Saito, H., & Ishii, H. (2002). Interferon therapy for hepatocellular carcinoma patients with low HCV-RNA levels. Hepato-Gastroenterology, 49(45), 724-729.

Interferon therapy for hepatocellular carcinoma patients with low HCV-RNA levels. / Miyaguchi, Shingo; Watanabe, Tetsu; Takahashi, Hiyori; Nakamura, Mitsuyasu; Saito, Hidetsugu; Ishii, Hiromasa.

In: Hepato-Gastroenterology, Vol. 49, No. 45, 2002, p. 724-729.

Research output: Contribution to journalArticle

Miyaguchi, S, Watanabe, T, Takahashi, H, Nakamura, M, Saito, H & Ishii, H 2002, 'Interferon therapy for hepatocellular carcinoma patients with low HCV-RNA levels', Hepato-Gastroenterology, vol. 49, no. 45, pp. 724-729.
Miyaguchi S, Watanabe T, Takahashi H, Nakamura M, Saito H, Ishii H. Interferon therapy for hepatocellular carcinoma patients with low HCV-RNA levels. Hepato-Gastroenterology. 2002;49(45):724-729.
Miyaguchi, Shingo ; Watanabe, Tetsu ; Takahashi, Hiyori ; Nakamura, Mitsuyasu ; Saito, Hidetsugu ; Ishii, Hiromasa. / Interferon therapy for hepatocellular carcinoma patients with low HCV-RNA levels. In: Hepato-Gastroenterology. 2002 ; Vol. 49, No. 45. pp. 724-729.
@article{b3fe6568955e4aebba5ad163678fb990,
title = "Interferon therapy for hepatocellular carcinoma patients with low HCV-RNA levels",
abstract = "Background/Aims: Interferon-alfa is widely used for the treatment of chronic hepatitis C, and has been thought to have a preventive effect on the development of hepatocellular carcinoma. Hepatocellular carcinoma develops from chronic liver diseases such as chronic hepatitis C or liver cirrhosis. We studied the effect of interferon for liver cirrhosis with hepatocellular carcinoma after treating hepatocellular carcinoma itself. Methodology: To evaluate the preventive effect of this drug on local recurrence and/or new development of primary tumor after clearance of hepatitis C virus, 46 patients with hepatocellular carcinoma with low HCV-RNA level were randomized to receive recombinant interferon-alfa 2b (n=22) or not (n=24) after being treated by transcatheter arterial chemoembolization and percutaneous ethanol injection therapy. In the interferon-treated group, patients received 3 million international units of interferon-alfa 2b intramuscularly three times a week for 4 months. In both groups, transcatheter arterial chemoembolization followed by percutaneous ethanol injection therapy was performed as an initial treatment and these therapies were repeated every 4-6 months. Serum HCV-RNA levels of all 46 patients were under 0.5Meq/mL by branched DNA probe assay. Results: In the interferon-treated group, 11 of the 22 (50{\%}) patients were HCV-RNA negative at the 6 months after completing the course of interferon therapy. HCV-RNA was undetectable during the observation period in 2 of the 24 (9.5{\%}) patients in the untreated group. The survival rate in the interferon-treated group was significantly higher than that in the untreated group (P=0.01 by the log-rank test). Though there was no significant difference in the incidence of local recurrence in both groups, the incidence of secondary hepatocellular carcinoma was significantly lower in the interferon-treated group than that in the untreated group. Cox proportional hazards regression analysis validated interferon treatment as an independent predictor of hepatocellular carcinoma prognosis. Conclusions: We concluded that, if HCV-RNA level is low, interferon may be a therapy of choice in combination with transcatheter arterial chemoembolization and percutaneous ethanol injection therapy for the treatment of hepatocellular carcinoma.",
keywords = "HCC, Interferon",
author = "Shingo Miyaguchi and Tetsu Watanabe and Hiyori Takahashi and Mitsuyasu Nakamura and Hidetsugu Saito and Hiromasa Ishii",
year = "2002",
language = "English",
volume = "49",
pages = "724--729",
journal = "Acta hepato-splenologica",
issn = "0172-6390",
publisher = "H.G.E. Update Medical Publishing Ltd.",
number = "45",

}

TY - JOUR

T1 - Interferon therapy for hepatocellular carcinoma patients with low HCV-RNA levels

AU - Miyaguchi, Shingo

AU - Watanabe, Tetsu

AU - Takahashi, Hiyori

AU - Nakamura, Mitsuyasu

AU - Saito, Hidetsugu

AU - Ishii, Hiromasa

PY - 2002

Y1 - 2002

N2 - Background/Aims: Interferon-alfa is widely used for the treatment of chronic hepatitis C, and has been thought to have a preventive effect on the development of hepatocellular carcinoma. Hepatocellular carcinoma develops from chronic liver diseases such as chronic hepatitis C or liver cirrhosis. We studied the effect of interferon for liver cirrhosis with hepatocellular carcinoma after treating hepatocellular carcinoma itself. Methodology: To evaluate the preventive effect of this drug on local recurrence and/or new development of primary tumor after clearance of hepatitis C virus, 46 patients with hepatocellular carcinoma with low HCV-RNA level were randomized to receive recombinant interferon-alfa 2b (n=22) or not (n=24) after being treated by transcatheter arterial chemoembolization and percutaneous ethanol injection therapy. In the interferon-treated group, patients received 3 million international units of interferon-alfa 2b intramuscularly three times a week for 4 months. In both groups, transcatheter arterial chemoembolization followed by percutaneous ethanol injection therapy was performed as an initial treatment and these therapies were repeated every 4-6 months. Serum HCV-RNA levels of all 46 patients were under 0.5Meq/mL by branched DNA probe assay. Results: In the interferon-treated group, 11 of the 22 (50%) patients were HCV-RNA negative at the 6 months after completing the course of interferon therapy. HCV-RNA was undetectable during the observation period in 2 of the 24 (9.5%) patients in the untreated group. The survival rate in the interferon-treated group was significantly higher than that in the untreated group (P=0.01 by the log-rank test). Though there was no significant difference in the incidence of local recurrence in both groups, the incidence of secondary hepatocellular carcinoma was significantly lower in the interferon-treated group than that in the untreated group. Cox proportional hazards regression analysis validated interferon treatment as an independent predictor of hepatocellular carcinoma prognosis. Conclusions: We concluded that, if HCV-RNA level is low, interferon may be a therapy of choice in combination with transcatheter arterial chemoembolization and percutaneous ethanol injection therapy for the treatment of hepatocellular carcinoma.

AB - Background/Aims: Interferon-alfa is widely used for the treatment of chronic hepatitis C, and has been thought to have a preventive effect on the development of hepatocellular carcinoma. Hepatocellular carcinoma develops from chronic liver diseases such as chronic hepatitis C or liver cirrhosis. We studied the effect of interferon for liver cirrhosis with hepatocellular carcinoma after treating hepatocellular carcinoma itself. Methodology: To evaluate the preventive effect of this drug on local recurrence and/or new development of primary tumor after clearance of hepatitis C virus, 46 patients with hepatocellular carcinoma with low HCV-RNA level were randomized to receive recombinant interferon-alfa 2b (n=22) or not (n=24) after being treated by transcatheter arterial chemoembolization and percutaneous ethanol injection therapy. In the interferon-treated group, patients received 3 million international units of interferon-alfa 2b intramuscularly three times a week for 4 months. In both groups, transcatheter arterial chemoembolization followed by percutaneous ethanol injection therapy was performed as an initial treatment and these therapies were repeated every 4-6 months. Serum HCV-RNA levels of all 46 patients were under 0.5Meq/mL by branched DNA probe assay. Results: In the interferon-treated group, 11 of the 22 (50%) patients were HCV-RNA negative at the 6 months after completing the course of interferon therapy. HCV-RNA was undetectable during the observation period in 2 of the 24 (9.5%) patients in the untreated group. The survival rate in the interferon-treated group was significantly higher than that in the untreated group (P=0.01 by the log-rank test). Though there was no significant difference in the incidence of local recurrence in both groups, the incidence of secondary hepatocellular carcinoma was significantly lower in the interferon-treated group than that in the untreated group. Cox proportional hazards regression analysis validated interferon treatment as an independent predictor of hepatocellular carcinoma prognosis. Conclusions: We concluded that, if HCV-RNA level is low, interferon may be a therapy of choice in combination with transcatheter arterial chemoembolization and percutaneous ethanol injection therapy for the treatment of hepatocellular carcinoma.

KW - HCC

KW - Interferon

UR - http://www.scopus.com/inward/record.url?scp=0036016691&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036016691&partnerID=8YFLogxK

M3 - Article

C2 - 12063979

AN - SCOPUS:0036016691

VL - 49

SP - 724

EP - 729

JO - Acta hepato-splenologica

JF - Acta hepato-splenologica

SN - 0172-6390

IS - 45

ER -